Your browser doesn't support javascript.
loading
Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study.
Kinnunen, Kirsi M; Cash, David M; Poole, Teresa; Frost, Chris; Benzinger, Tammie L S; Ahsan, R Laila; Leung, Kelvin K; Cardoso, M Jorge; Modat, Marc; Malone, Ian B; Morris, John C; Bateman, Randall J; Marcus, Daniel S; Goate, Alison; Salloway, Stephen P; Correia, Stephen; Sperling, Reisa A; Chhatwal, Jasmeer P; Mayeux, Richard P; Brickman, Adam M; Martins, Ralph N; Farlow, Martin R; Ghetti, Bernardino; Saykin, Andrew J; Jack, Clifford R; Schofield, Peter R; McDade, Eric; Weiner, Michael W; Ringman, John M; Thompson, Paul M; Masters, Colin L; Rowe, Christopher C; Rossor, Martin N; Ourselin, Sebastien; Fox, Nick C.
Afiliação
  • Kinnunen KM; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK.
  • Cash DM; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK; Department of Medical Physics and Bioengineering, Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK. Electronic address: d.cash@ucl.ac.uk.
  • Poole T; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK; Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.
  • Frost C; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK; Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.
  • Benzinger TLS; Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
  • Ahsan RL; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK.
  • Leung KK; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK.
  • Cardoso MJ; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK; Department of Medical Physics and Bioengineering, Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK.
  • Modat M; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK; Department of Medical Physics and Bioengineering, Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK.
  • Malone IB; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK.
  • Morris JC; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
  • Bateman RJ; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
  • Marcus DS; Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
  • Goate A; Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Salloway SP; Department of Neurology, Butler Hospital, Warren Alpert Medical School, Brown University, Providence, RI, USA.
  • Correia S; Department of Neurology, Butler Hospital, Warren Alpert Medical School, Brown University, Providence, RI, USA.
  • Sperling RA; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Chhatwal JP; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Mayeux RP; Department of Neurology, Columbia University Medical Center, New York, NY, USA.
  • Brickman AM; Department of Neurology, Columbia University Medical Center, New York, NY, USA.
  • Martins RN; Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
  • Farlow MR; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Ghetti B; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Saykin AJ; Department of Radiology and Imaging Sciences, Centre for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Jack CR; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Schofield PR; Neuroscience Research Australia, Randwick, NSW, Australia; School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
  • McDade E; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
  • Weiner MW; Department of Radiology, School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Ringman JM; Department of Neurology, Keck USC School of Medicine, Los Angeles, CA, USA.
  • Thompson PM; Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA.
  • Masters CL; The Florey Institute, University of Melbourne, Parkville, VIC, Australia.
  • Rowe CC; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia; Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC, Australia.
  • Rossor MN; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK.
  • Ourselin S; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK; Department of Medical Physics and Bioengineering, Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK.
  • Fox NC; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK.
Alzheimers Dement ; 14(1): 43-53, 2018 01.
Article em En | MEDLINE | ID: mdl-28738187
ABSTRACT

INTRODUCTION:

Identifying at what point atrophy rates first change in Alzheimer's disease is important for informing design of presymptomatic trials.

METHODS:

Serial T1-weighted magnetic resonance imaging scans of 94 participants (28 noncarriers, 66 carriers) from the Dominantly Inherited Alzheimer Network were used to measure brain, ventricular, and hippocampal atrophy rates. For each structure, nonlinear mixed-effects models estimated the change-points when atrophy rates deviate from normal and the rates of change before and after this point.

RESULTS:

Atrophy increased after the change-point, which occurred 1-1.5 years (assuming a single step change in atrophy rate) or 3-8 years (assuming gradual acceleration of atrophy) before expected symptom onset. At expected symptom onset, estimated atrophy rates were at least 3.6 times than those before the change-point.

DISCUSSION:

Atrophy rates are pathologically increased up to seven years before "expected onset". During this period, atrophy rates may be useful for inclusion and tracking of disease progression.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Doença de Alzheimer Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Alzheimers Dement Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Doença de Alzheimer Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Alzheimers Dement Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido